CompletedPhase 3NCT01224210
Ambrisentan in Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial
Studying Pulmonary arterial hypertension associated with portal hypertension
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Tufts Medical Center
- Principal Investigator
- Ioana Preston, MDTufts Medical Center
- Intervention
- Ambrisentan(drug)
- Enrollment
- 30 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2010 – 2020
Study locations (6)
- UCSD Medical Center, La Jolla, California, United States
- Mayo Clinic Florida, Jacksonville, Florida, United States
- Tufts Medical Center, Boston, Massachusetts, United States
- University of North Carolina, Chapel Hill, North Carolina, United States
- The Ohio State University Medical Center, Columbus, Ohio, United States
- UT Southwestern Medical Center, Dallas, Texas, United States
Collaborators
Gilead Sciences
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01224210 on ClinicalTrials.gov